Identification, pharmacologic considerations, and management of prostatitis.

Area of Science:

• Urology
• Pharmacology

Background:

• Prostatitis involves prostate inflammation with diverse causes, sometimes without identifiable pathogens.
• Effective treatment hinges on accurate diagnosis, which can be challenging due to undetectable microorganisms in chronic cases.

Purpose of the Study:

• To review current identification and treatment strategies for prostatitis.
• To explore both pharmacologic and non-pharmacologic interventions for prostatitis management.

Main Methods:

• Literature search of MEDLINE, International Pharmaceutical Abstracts, and EMBASE databases (1966-2010).
• Exclusion of studies on prostate cancer, benign prostatic hypertrophy, and prostate-related procedures.
• Focus on randomized controlled trials evaluating prostatitis treatments.

Main Results:

• Fluoroquinolones are effective for bacterial prostatitis due to excellent prostate tissue penetration.
• Levofloxacin demonstrated high clinical success rates in chronic bacterial prostatitis.
• Alpha-blockers show improved efficacy with longer treatment durations in treatment-naïve patients.
• Stepwise therapy (antibiotics, then bioflavonoids, then alpha-blockers) effectively reduced chronic prostatitis symptoms for up to a year.

Conclusions:

• Accurate prostatitis classification and understanding medication pharmacologic profiles are key to effective treatment.
• Fluoroquinolones are primary agents for bacterial prostatitis and show promise in some chronic cases.
• Anti-inflammatory or antiadrenergic agents may be required adjuncts or alternatives to antimicrobials.